论文部分内容阅读
目的观察宫腔镜电切术配合生化汤加味治疗早期子宫内膜癌的临床疗效。方法将96例早期子宫内膜癌患者随机分为对照组和观察组各48例,对照组行宫腔镜电切术治疗,观察组在对照组治疗基础上加用生化汤加味治疗,观察2组治疗后的住院情况、疼痛指数、满意度、复发率、生存质量调查问卷(EORTC QLQ-C30)评分及1年后妊娠情况。结果观察组治疗后VAS评分明显低于对照组,治疗满意度评分明显高于对照组(P均<0.05),住院时间及发热时间明显短于对照组(P均<0.05);观察组治疗后第1,2,3年复发率均明显低于对照组(P均<0.05);治疗后1年、2年观察组EORTC QLQ-C30评分均较治疗前明显降低(P<0.05),且明显低于对照组(P均<0.05),而对照组无明显变化(P均>0.05);观察组受孕率及足月生产率明显高于对照组(P<0.05),流产及早产率均明显低于对照组(P均<0.05)。结论宫腔镜电切术配合生化汤加味治疗早期子宫内膜癌能明显提高患者的生存质量及治疗满意度,缩短治疗时间,减少术后复发,提高受孕率及足月生产率,可在临床推广应用。
Objective To observe the clinical efficacy of hysteroscopic electrotomy combined with biochemical decoction in the treatment of early endometrial cancer. Methods 96 cases of early endometrial cancer were randomly divided into control group and observation group of 48 cases, the control group were treated by hysteroscopic electrotomy, the observation group on the basis of the control group plus biochemical soup plus treatment, the observation group 2 Hospitalization after treatment, pain index, satisfaction, relapse rate, quality of life questionnaire (EORTC QLQ-C30) and pregnancy after 1 year. Results The score of VAS in observation group was significantly lower than that in control group, and the score of treatment satisfaction was significantly higher than that of control group (P <0.05). The length of hospitalization and fever were significantly shorter in observation group than in control group (P <0.05) The relapse rates in the first, second, and third years were significantly lower than those in the control group (all P <0.05). EORTC QLQ-C30 scores in the observation group at 1 year and 2 years after treatment were significantly lower than those before treatment (P <0.05) (P <0.05). The pregnancy rate and full-term productivity of the observation group were significantly higher than those of the control group (P <0.05), and the rates of miscarriage and premature delivery were significantly lower In the control group (all P <0.05). Conclusion Hysteroscopic resection combined with biochemical decoction for the treatment of early endometrial cancer can significantly improve the patient’s quality of life and satisfaction of treatment, shorten the treatment time, reduce postoperative recurrence, improve pregnancy rate and full-term productivity in the clinical promotion application.